Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]

• Published in: International journal of chronic obstructive pulmonary disease Vol. 9; no. default; p. 85
• Main Authors: Dahl, Ronald, Jadayel, Dalal, Alagappan, Vijay, Chen, Hungta, Banerji, Donald
• Format: Journal Article
• Language: English
• Published: London Dove Medical Press Limited 01-01-2014; Dove Medical Press Ltd; Dove Medical Press
• Subjects: Corrigendum
• ISSN: 1178-2005; 1176-9106; 1178-2005
• DOI: 10.2147/COPD.S56963

Dahl R, Jadayel D, Alagappan VKT, Chen H, Banerji D. Int J Chron Obstruct Pulmon Dis. 2013;8:501-508.On page 501, note that in the Results section of the Abstract, the sentence "Trough FEV1 at week 4 for QVA149 and IND+GLY was 1.46 L ± 0.02 and 1.46 L ± 0.18, respectively." should read "Trough FEV1 at week 4 for QVA149 and IND+GLY was 1.5 L ± 0.02." On page 505, note that the sentence "The least squares mean ± standard error (LSM ± SE) trough FEV1 at week 4 for QVA149 and for the free-dose combination of IND+GLY was 1.5 L ± 0.02 and 1.5 L ± 0.18, respectively (Figure 3)." should read "The least squares mean ± standard error (LSM ± SE) trough FEV1 at week 4 for QVA149 and for the free-dose combination of IND+GLY was 1.5 L ± 0.02 (Figure 3)."On page 505, note that the confidence interval for Figure 3 was incorrect, and the confidence intervals and y-axis for Figure 4 were also incorrect. The full and correct figures are given here.Read the original article